Trials / Completed
CompletedNCT00929565
Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy
Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- University of Oklahoma · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway. The investigators plan to measure these factors prior to and after bronchoscopy.
Detailed description
This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.
Conditions
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2010-06-01
- Completion
- 2011-10-01
- First posted
- 2009-06-29
- Last updated
- 2012-04-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00929565. Inclusion in this directory is not an endorsement.